Hims & Hers Health stock holds steady as net loss replaces prior year profit

Traders Union
All News
Financial News
Hims & Hers Health up 0.41% today

Highlights

Hims & Hers Health posted a net loss of $92.1 million for Q1, reversing last year's profitability and missing earnings expectations.
Management's pivot in weight-loss drug strategy introduces additional uncertainty around future growth prospects and revenue visibility.
HIMS trades below major moving averages with mixed momentum signals, likely remaining rangebound between $23.75 and $25.75 in the near term.

Net loss and earnings miss weigh on investor confidence as growth plans shift

Hims & Hers Health reported a net loss of $92.1 million for the first quarter, marking a notable reversal from net income of $49.5 million a year ago and highlighting operational and strategic challenges for the company. This result was accompanied by a loss per share of $0.40, which fell short of Wall Street expectations and contributed to a weaker earnings profile. The company also shifted its approach to weight-loss drugs this quarter, prompting uncertainty about future growth strategies and revenue streams.

Upside capped as resistance dominates despite persistent oversold momentum

SMA-20 at $27.62 and SMA-200 at $36.05 remain above the current price, establishing higher resistance, while the SMA-50 sits just below at $23.98 to provide immediate support. The Ichimoku Kijun level at $25.41 acts as the next technical resistance. On the momentum side, the D1 MACD presents a strong buy signal, but oscillators such as the RSI and CCI both signal oversold territory, while BBP confirms sellers remain dominant intraday. Stoch RSI is also in oversold conditions, suggesting near-term downside exhaustion; meanwhile, the Awesome Oscillator is neutral and ADX reflects only modest bullish momentum.

Rangebound outlook favored as probability of breakout remains low

Over the next five trading days, HIMS is expected to remain within a typical volatility band between $23.75 and $25.75. Probability analysis suggests less than a 20% chance of a meaningful price increase in this period, favoring a rangebound or mildly downside scenario. A break above $25.41 would open room for a push toward $25.75, while a downside breach below $23.75 could trigger accelerated weakness toward lower support.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers Health facing short-term challenges due to recent earnings volatility and a shift in strategy. He notes that despite the net loss and EPS miss, market momentum is slowly tilting positive, with oversold conditions hinting at a possible rebound. Macro sentiment remains cautious, but the company’s adjustment to growth plans could attract renewed attention if support holds. "If HIMS can stabilize above $23.98, I believe buyers could regain control and open the way for a fresh move toward higher resistance levels."

Earlier, analysts noted that Hims & Hers Health was under sustained selling pressure amid operational headwinds and a transition toward branded GLP-1 therapies. With current technical signals still reflecting near-term downside exhaustion and muted upside probabilities, traders should monitor for a potential volatility breakout if the price decisively breaches support at $23.75 or resistance at $25.41.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.